Matthew Vanneman
Stanford University
46 Papers
72 Citations
Matthew Vanneman is an academic researcher from Stanford University. The author has contributed to research in topics: Medicine & Perioperative. The author has an hindex of 8, co-authored 22 publications. Previous affiliations of Matthew Vanneman include Harvard University & Brigham and Women's Hospital.
Chat about Author
Papers
Combining immunotherapy and targeted therapies in cancer treatment
TL;DR: Targeted therapies and cytotoxic agents also modulate immune responses, which raises the possibility that these treatment strategies might be effectively combined with immunotherapy to improve clinical outcomes.
1.5K
Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model.
Baochun Zhang,Sven Kracker,Tomoharu Yasuda,Stefano Casola,Stefano Casola,Matthew Vanneman,Cornelia Hömig-Hölzel,Zhe Wang,Emmanuel Derudder,Shuang Li,Tirtha Chakraborty,Shane E. Cotter,Shohei Koyama,Treeve Currie,Gordon J. Freeman,Jeffery L. Kutok,Scott J. Rodig,Glenn Dranoff,Klaus Rajewsky,Klaus Rajewsky +19 more
TL;DR: A central role for LMP1 in the surveillance and transformation of EBV-infected B cells in vivo is indicated, a preclinical model for B cell lymphomagenesis in immunosuppressed patients is established, and a new therapeutic approach is validated.
168
Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation
Vincent T. Ho,Matthew Vanneman,Haesook T. Kim,Tetsuro Sasada,Yoon Joong Kang,Mildred Pasek,Corey Cutler,John Koreth,Edwin P. Alyea,Stefanie Sarantopoulos,Joseph H. Antin,Jerome Ritz,Christine Canning,Jeffery L. Kutok,Martin C. Mihm,Glenn Dranoff,Robert J. Soiffer +16 more
TL;DR: A Phase I clinical trial in which high-risk acute myeloid leukemia or myelodysplasia patients were immunized with irradiated, autologous, GM-CSF-secreting tumor cells early after allogeneic, nonmyeloablative HSCT raises the possibility that this combinatorial immunotherapy might potentiate graft-versus-leukemia in patients.
107
Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction
Catia Fonseca,Robert J. Soiffer,Vincent T. Ho,Matthew Vanneman,Masahisa Jinushi,Jerome Ritz,Donna Neuberg,Richard Stone,Daniel J. DeAngelo,Glenn Dranoff +9 more
TL;DR: In this paper, the most frequently recognized clone was protein disulfide isomerase (PDI) and high titer antibodies to human PDI were similarly induced in an acute myeloid leukemia patient who achieved a complete response after vac-cination with irradiated, autologous GM-CSF-secreting tumor cells in the setting of allogeneic bone marrow transplantation.
43
Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction Short title: Immunogenicity of protein disulfide isomerases
Richard Stone,D. DeAngelo,Glenn Dranoff,Catia Fonseca,Robert J. Soiffer,Vincent T. Ho,Matthew Vanneman,Masahisa Jinushi,Jerome Ritz,Donna Neuberg,Dana C +10 more
- 01 Jan 2008
TL;DR: The unexpected immunogenicity of PDIs is revealed and the possibility that these gene products might serve as targets for therapeutic monoclonal antibodies is raised.
32